An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration.
Phase of Trial: Phase IV
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RE-VIEW
- Sponsors Regeneron Pharmaceuticals
- 28 Jan 2016 Last checked against ClinicalTrials.gov record.
- 12 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Apr 2015 New trial record